Aurora Cannabis Inc. (ACB.TO)
CAD 5.91
(1.72%)
CAD 5.91
(1.72%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 158.53 Million CAD | -14.33% |
| 2022 | 185.05 Million CAD | -23.09% |
| 2021 | 240.6 Million CAD | 6.89% |
| 2020 | 225.08 Million CAD | -50.08% |
| 2019 | 450.93 Million CAD | -1.29% |
| 2018 | 456.84 Million CAD | 269.53% |
| 2017 | 123.62 Million CAD | 381.1% |
| 2016 | 25.69 Million CAD | 278.29% |
| 2015 | 6.79 Million CAD | 55.55% |
| 2014 | 4.36 Million CAD | 1324.92% |
| 2013 | 306.48 Thousand CAD | -23.93% |
| 2012 | 402.87 Thousand CAD | 21.79% |
| 2011 | 330.78 Thousand CAD | 64.3% |
| 2010 | 201.33 Thousand CAD | 248.53% |
| 2009 | 57.76 Thousand CAD | -68.97% |
| 2008 | 186.18 Thousand CAD | -18.71% |
| 2007 | 229.04 Thousand CAD | 18282.58% |
| 2006 | 1246.00 CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 43.74 Million CAD | 3.85% |
| 2023 Q1 | 32.38 Million CAD | -20.47% |
| 2023 FY | 158.53 Million CAD | -14.33% |
| 2023 Q2 | 42.12 Million CAD | 30.07% |
| 2022 FY | 185.05 Million CAD | -23.09% |
| 2022 Q4 | 40.72 Million CAD | -1.32% |
| 2022 Q2 | 52.39 Million CAD | 4.37% |
| 2022 Q1 | 50.2 Million CAD | -27.04% |
| 2022 Q3 | 41.26 Million CAD | -21.24% |
| 2021 Q4 | 68.8 Million CAD | 20.37% |
| 2021 Q3 | 57.16 Million CAD | -11.23% |
| 2021 Q1 | 50.23 Million CAD | -18.61% |
| 2021 Q2 | 64.39 Million CAD | 28.18% |
| 2021 FY | 240.6 Million CAD | 6.89% |
| 2020 Q1 | 67.84 Million CAD | 6.6% |
| 2020 Q2 | 42.71 Million CAD | -37.03% |
| 2020 Q3 | 52.8 Million CAD | 23.61% |
| 2020 Q4 | 61.72 Million CAD | 16.89% |
| 2020 FY | 225.08 Million CAD | -50.08% |
| 2019 FY | 450.93 Million CAD | -1.29% |
| 2019 Q4 | 63.64 Million CAD | -41.97% |
| 2019 Q3 | 109.67 Million CAD | -25.63% |
| 2019 Q2 | 147.46 Million CAD | 13.31% |
| 2019 Q1 | 130.14 Million CAD | 11.04% |
| 2018 Q4 | 117.2 Million CAD | -8.48% |
| 2018 FY | 456.84 Million CAD | 269.53% |
| 2018 Q3 | 128.05 Million CAD | 20.08% |
| 2018 Q2 | 106.64 Million CAD | 1.62% |
| 2018 Q1 | 104.94 Million CAD | 73.97% |
| 2017 FY | 123.62 Million CAD | 381.1% |
| 2017 Q4 | 60.32 Million CAD | 84.9% |
| 2017 Q3 | 32.62 Million CAD | 56.91% |
| 2017 Q2 | 20.79 Million CAD | 110.28% |
| 2017 Q1 | 9.88 Million CAD | 23.54% |
| 2016 Q1 | 3.36 Million CAD | 32.24% |
| 2016 Q2 | 6.73 Million CAD | 100.44% |
| 2016 Q3 | 7.59 Million CAD | 12.75% |
| 2016 Q4 | 8 Million CAD | 5.37% |
| 2016 FY | 25.69 Million CAD | 278.29% |
| 2015 Q1 | 1.18 Million CAD | 429.77% |
| 2015 Q3 | 1.52 Million CAD | -1.51% |
| 2015 Q2 | 1.54 Million CAD | 30.76% |
| 2015 Q4 | 2.54 Million CAD | 66.91% |
| 2015 FY | 6.79 Million CAD | 55.55% |
| 2014 Q2 | 1.18 Million CAD | 118.47% |
| 2014 Q4 | -358.55 Thousand CAD | -152.01% |
| 2014 Q3 | 689.46 Thousand CAD | -41.85% |
| 2014 Q1 | 542.73 Thousand CAD | 288.14% |
| 2014 FY | 4.36 Million CAD | 1324.92% |
| 2013 FY | 306.48 Thousand CAD | -23.93% |
| 2013 Q2 | 30.77 Thousand CAD | -25.56% |
| 2013 Q3 | 94.54 Thousand CAD | 207.19% |
| 2013 Q4 | 139.82 Thousand CAD | 47.9% |
| 2013 Q1 | 41.34 Thousand CAD | -61.45% |
| 2012 Q1 | 151.76 Thousand CAD | -24.9% |
| 2012 Q3 | 75.2 Thousand CAD | 6.71% |
| 2012 FY | 402.87 Thousand CAD | 21.79% |
| 2012 Q2 | 70.47 Thousand CAD | -53.56% |
| 2012 Q4 | 107.24 Thousand CAD | 42.6% |
| 2011 Q1 | 44.52 Thousand CAD | -59.71% |
| 2011 Q4 | 202.08 Thousand CAD | 346.0% |
| 2011 FY | 330.78 Thousand CAD | 64.3% |
| 2011 Q2 | 38.86 Thousand CAD | -12.71% |
| 2011 Q3 | 45.31 Thousand CAD | 16.59% |
| 2010 Q4 | 110.51 Thousand CAD | 166.96% |
| 2010 Q1 | 37.74 Thousand CAD | 54.79% |
| 2010 Q2 | 47.77 Thousand CAD | 26.57% |
| 2010 FY | 201.33 Thousand CAD | 248.53% |
| 2010 Q3 | 41.39 Thousand CAD | -13.35% |
| 2009 FY | 57.76 Thousand CAD | -68.97% |
| 2009 Q4 | 24.38 Thousand CAD | 55.51% |
| 2009 Q3 | 15.68 Thousand CAD | 17.9% |
| 2009 Q2 | 13.3 Thousand CAD | -46.71% |
| 2009 Q1 | 24.95 Thousand CAD | 0.94% |
| 2008 Q4 | 24.72 Thousand CAD | -32.62% |
| 2008 Q2 | 32.4 Thousand CAD | -64.92% |
| 2008 FY | 186.18 Thousand CAD | -18.71% |
| 2008 Q3 | 36.69 Thousand CAD | 13.25% |
| 2008 Q1 | 92.36 Thousand CAD | 128.63% |
| 2007 Q3 | 22.26 Thousand CAD | -86.5% |
| 2007 Q1 | 1425.00 CAD | 0.0% |
| 2007 Q4 | 40.39 Thousand CAD | 81.46% |
| 2007 Q2 | 164.96 Thousand CAD | 11476.14% |
| 2007 FY | 229.04 Thousand CAD | 18282.58% |
| 2006 FY | 1246.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Avicanna Inc. | 14.59 Million CAD | -986.501% |
| Avant Brands Inc. | 5.65 Million CAD | -2701.537% |
| Cardiol Therapeutics Inc. | 29.53 Million CAD | -436.744% |
| Crescita Therapeutics Inc. | 12.32 Million CAD | -1186.843% |
| Knight Therapeutics Inc. | 155.54 Million CAD | -1.927% |
| MediPharm Labs Corp. | 23.08 Million CAD | -586.821% |
| OrganiGram Holdings Inc. | 277.81 Million CAD | 42.933% |
| Canopy Growth Corporation | 308.61 Million CAD | 48.628% |
| Willow Biosciences Inc. | 7.55 Million CAD | -1998.742% |
| Auxly Cannabis Group Inc. | 40.28 Million CAD | -293.573% |